Daratumumab and hyaluronidase-fihj news

All news on Daratumumab and hyaluronidase-fihj (also known as DARZALEX FASPRO and DARZALEX): plants, production capacities, investments and involved companies.

6 November 2025
Johnson & Johnson's DARZALEX FASPRO®: First FDA-Approved Treatment for High-Risk Smoldering Multiple Myeloma
DARZALEX FASPRO® reduces progression risk to active multiple myeloma by 51% in high-risk patients, marking a shift in treatment strategy.

Who will be producing Daratumumab and hyaluronidase-fihj in the future?

Find out with chemXplore Analytics